BioPharmSignal logoBioPharmSignal

Biotech News

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Vivani Medical (VANI)Vivani MedicalCompany update

VANI (VANI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is vani.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

VANIVivani Medical2026-06-25 11:30 EST

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

VANIVivani Medical2026-08-06 12:00 EST

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

View all latest news

Vivani Medical

Long-Acting Implant Company Vivani Medical develops miniature drug implants intended to provide multi-month delivery of established medicines. NanoPortal Technology The NanoPortal platform controls drug diffusion through a compact implant, with the goal of improving adherence and reducing treatment burden. NPM-139 NPM-139 is an...

Recent company news

VANIVivani Medical2026-08-13 20:05 EST

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

VANIVivani Medical2026-08-06 12:00 EST

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

VANIVivani Medical2026-07-14 20:03 EST

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

VANIVivani Medical2026-07-07 11:35 EST

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

VANIVivani Medical2026-07-02 12:00 EST

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Stock data

Close
1.38 USD
Market cap
112.11M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States